Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nomura Holdings Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Nomura Holdings Inc trades at $9.66 (market cap $27.88B). The key difference: Nomura Holdings Inc is far larger — about 33.7× Amphastar Pharmaceuticals Inc's market cap, and Nomura Holdings Inc pays a 3.35% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NMR | |
|---|---|---|
Market Cap | $826.08M | $27.88B |
Sector | Health | Financials |
52-Week High | $30.81 | $9.66 |
52-Week Low | $16.87 | $6.30 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Nomura Holdings (NMR) trades at $9.66, up 1.26% today, with a bullish technical signal from moving averages. The company reported record annual revenue of $1.66 trillion and net income of $340.74 billion for 2025, driving a net income margin of 20.49%. Recent news highlights strong wholesale revenue growth and strategic acquisitions, while analyst consensus shows a hold-heavy rating with 33% buy recommendations.
The outlook is mixed; robust profitability and expansion in core segments support upside, but consecutive earnings misses and rising debt-to-asset ratios pose risks. Investor sentiment is cautiously optimistic, with technical indicators suggesting near-term momentum but overbought conditions on shorter-term RSI readings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
